Who is Pear and what are prescription digital therapeutics? Why are PDTs so important to the continuum of care, especially when it comes to mental health? In this fascinating interview, Dr. Andrew Cutler interviews Dr. Corey McMann, the President and CEO of Pear Therapeutics about the importance of this technology in treating mental health.

Corey M. McCann, MD, PhD, is the President and CEO of Pear Therapeutics. Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system expertise group, advising clients across the healthcare value chain.

E130 - Therapeutics in the Digital Age: Redefining Care with Software-Based Medicines